Product Introduction
| Item | Specification |
| Product Name | Sunitinib |
| Synonyms | SU11248; Sutent; 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide |
| CAS Number | 557795-19-4 |
| Molecular Formula | C₂₂H₂₇FN₄O₂ |
| Molecular Weight | 398.47 g/mol |
| Appearance | Yellow to orange crystalline powder, odorless, stable crystal form under sealed dark and dry conditions |
| Purity (HPLC) | ≥98.0% / ≥99.0% (Research Grade / Pharma API Grade, customizable) |
| Loss on Drying | ≤ 0.2% |
| Residue on Ignition | ≤ 0.1% |
| Testing Method | HPLC / NMR / Mass Spectrometry / IR Spectrum / Cell Level Activity Detection |
| Production Method | Fluorinated Indolinone Heterocyclic Synthesis & Multi-Stage Purification & Low-Temperature Recrystallization |
| Melting Point | 189–191°C (lit.) |
| Boiling Point | 572.1°C at 760 mmHg |
| Density | 1.22 g/cm³ at 25°C |
| Flash Point | 300.8°C |
| Solubility | Soluble in DMSO, methanol, ethanol and acidic aqueous solutions, slightly soluble in neutral water; stable in dry environment, sensitive to strong light, high temperature and humidity |
| Core Feature | Fluorinated indolinone heterocyclic compound, multi-target RTK inhibitor, potent anti-angiogenesis and tumor proliferation inhibitory activity |
| Package | 1g/5g/10g sealed amber bottle, 100g/1kg drum; vacuum moisture-proof packaging, custom specification available |
| Storage | Store in vacuum-sealed, low-temperature, dark and dry conditions; avoid strong light, high temperature and humid environment to prevent oxidation and structural degradation |
| Shelf Life | 24 months under standard low-temperature sealed storage |
Product Description
Our Sunitinib (SU11248) is a high-purity fluorinated indolinone heterocyclic small-molecule inhibitor with stable molecular structure and complete targeted anti-tumor pharmacological activity, available in premium research grade and pharmaceutical API grade. Sunitinib (CAS 557795-19-4) is a landmark multi-target receptor tyrosine kinase (RTK) inhibitor derived from modified indole heterocyclic skeleton. Featuring unique fluoro-substituted indolinone and pyrrole carboxamide structural modification, it efficiently targets and inhibits multiple key tumor signal receptors, including VEGFR, PDGFR, c-KIT and FLT3. Differentiated from single-target kinase inhibitors, Sunitinib delivers broad-spectrum anti-angiogenic and anti-proliferative efficacy, becoming a core tool compound and clinical first-line API for tumor pharmacology research and targeted therapy. As a professional bulk Sunitinib supplier, we provide low-impurity, high-activity, batch-stable Sunitinib raw materials for global tumor pharmacology laboratories, anti-cancer drug R&D institutions and heterocyclic pharmaceutical intermediate enterprises.
Sunitinib occupies a pivotal core position in targeted tumor pharmacology, tumor angiogenesis mechanism research and indole heterocyclic medicinal chemistry. Officially FDA-approved in 2006, it is the first small-molecule multi-target RTK inhibitor simultaneously authorized for renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) treatment. Its core pharmacological mechanism focuses on blocking tumor angiogenesis and inhibiting malignant cell proliferation: by suppressing VEGFR-mediated vascular endothelial growth signal, it cuts off tumor nutrient supply and inhibits microangiogenesis; by targeting PDGFR and c-KIT mutation pathways, it effectively inhibits the proliferation and metastasis of drug-resistant GIST and solid tumor cells. In scientific research, Sunitinib is widely used for exploring RTK signal transduction, tumor microenvironment angiogenesis, tumor drug resistance mechanism and targeted drug efficacy screening. In pharmaceutical synthesis, its fluorinated indolinone skeleton provides valuable structural modification sites, supporting the optimization and development of new-generation high-efficiency, low-toxicity multi-target anti-tumor derivatives. Compared with ordinary low-purity Sunitinib products with fluorinated by-products and unstable kinase inhibitory activity, our high-purity purified product completely removes synthetic intermediates, residual solvents and oxidative degradation impurities, ensuring single-component purity and stable targeted activity for accurate, repeatable tumor experimental data and reliable new drug R&D results.
Manufactured by Shaanxi BAISFU Bio-Engineering Co., Ltd., our premium Sunitinib adopts advanced fluorinated indolinone precision synthesis combined with low-temperature oxygen-free cyclization reaction and multi-stage gradient recrystallization purification process. The entire production process strictly controls fluorination reaction ratio, temperature and pH value, thoroughly eliminating unreacted indolinone raw materials, fluorine-containing impurities and amide condensation by-products. By avoiding high-temperature induced molecular isomerization and activity attenuation, the process fully retains the complete active heterocyclic skeleton and efficient multi-target RTK inhibitory activity of Sunitinib. The finished product presents uniform yellow to orange crystalline powder, stable crystal form, no caking, no fading and no discoloration, fully complying with high-standard tumor research grade and pharmaceutical API raw material grade quality requirements.
Every batch of Sunitinib undergoes strict multi-dimensional quality inspection, including HPLC high-precision purity analysis, NMR structural verification, mass spectrometry molecular identification and cell-level tumor inhibitory activity testing. It ensures zero invalid impurity interference, ultra-low trace residues and consistent batch efficacy, providing reliable raw material guarantee for tumor angiogenesis research, multi-kinase pathway mechanism experiments and targeted anti-cancer drug synthesis. The product features stable solubility in organic solvents and acidic aqueous solutions, excellent biochemical stability in cell and animal experiment environments and outstanding experimental repeatability, fully meeting the strict raw material requirements of in vitro tumor cell inhibition tests, in vivo tumor model efficacy verification and new targeted drug formula development.
We maintain sufficient low-temperature inventory and complete qualification documents for bulk Sunitinib supply. Whether you need standard multi-target RTK inhibitor monomers for tumor pharmacological research, core reference substances for targeted anti-tumor drug evaluation, or high-purity fluorinated indolinone heterocyclic intermediates for custom derivative synthesis, our premium Sunitinib is a high-cost-performance and high-value biological fine chemical product choice for global buyers.
Functions & Benefits
Broad-Spectrum Multi-Target RTK Inhibitor (Core Benefit)
Sunitinib is a classic high-efficiency multi-target tyrosine kinase inhibitor, precisely acting on key tumor targets such as VEGFR, PDGFR, c-KIT and FLT3. It dual-inhibits tumor angiogenesis and malignant cell proliferation, serving as the gold-standard tool compound for targeted tumor pharmacology and multi-kinase pathway research.
Unique Fluorinated Indolinone Heterocyclic Structure
As a high-value fluorine-modified indole heterocyclic derivative, Sunitinib enriches the structural diversity of indole anti-tumor drugs. Its fluoro-substituted indolinone and pyrrole amide integrated skeleton provides critical templates for heterocyclic structure-activity relationship research and innovative targeted drug development.
Dual Anti-Angiogenesis & Anti-Tumor Proliferation Efficacy
High-purity Sunitinib stably exerts dual anti-tumor effects: blocking tumor neovascularization to cut off nutrient supply, and inhibiting mutated kinase-driven tumor cell proliferation and invasion. It is the primary positive control drug for solid tumor and drug-resistant tumor targeted therapy experiments.
Low-Impurity Purification & Ultra-Stable Pharmacological Activity
Our Sunitinib adopts low-temperature oxygen-free anti-oxidation and de-fluorination impurity removal technology, eliminating invalid fluorinated by-products and oxidative degradation substances generated during synthesis. It solves the problem of decreased kinase inhibitory activity and unstable experimental data of conventional products, ensuring long-term stable targeted pharmacological efficacy.
Strict Batch Consistency & High Experimental Repeatability
Synthesized and recrystallized under constant low-temperature sterile conditions, Sunitinib eliminates process quality fluctuations. The product has uniform crystal form, stable molecular structure and consistent batch multi-target inhibitory activity, suitable for long-term tumor mechanism research and high-precision anti-cancer drug screening experiments.
Excellent Solubility & Wide Experimental Adaptability
Sunitinib has good solubility in common organic solvents and acidic aqueous solutions, easy to prepare into experimental stock solutions and targeted drug formula systems. It maintains stable activity in conventional cell culture and animal experiment environments, perfectly adapting to tumor cell inhibition tests, in vivo xenograft model experiments and pharmaceutical formulation research.
Applications
Multi-Target RTK Pathway & Tumor Pharmacology Research
Used as a standard high-purity multi-kinase inhibitor reagent for studying VEGFR/PDGFR/c-KIT signal transduction, tumor angiogenesis and malignant proliferation regulation mechanisms. Widely applied in oncology pharmacology laboratories and tumor research institutions.
Renal Cell Carcinoma & GIST Drug Resistance Mechanism Study
Served as the core specific positive drug for RCC targeted therapy and imatinib-resistant GIST model experiments, supporting the efficacy verification and mechanism exploration of new anti-tumor targeted active substances.
Targeted Anti-Cancer API R&D & Pharmacological Evaluation
Applied as a classic reference compound for new multi-target anti-tumor drug development, guiding structural optimization, efficacy screening and safety evaluation of indole heterocyclic targeted therapeutic molecules.
Fluorinated Indolinone Heterocyclic Derivative Synthesis
Used as a high-value fluorine-modified indole heterocyclic skeleton intermediate for the synthesis of new high-efficiency targeted anti-tumor derivatives, supporting innovative R&D of low-toxicity multi-target anti-cancer pharmaceutical intermediates.
Laboratory Pharmacological Verification & Teaching Research
Provided as standard high-purity Sunitinib reagent for oncology pharmacology teaching experiments, multi-kinase inhibitory efficacy comparative tests and indole heterocyclic structure-activity relationship verification, ensuring accurate and stable experimental data for scientific research and teaching work.
FAQ
Q1: What is Sunitinib mainly used for?
A: Sunitinib is a classic fluorinated indolinone-based multi-target RTK inhibitor. It is mainly used for tumor angiogenesis mechanism research, renal cell carcinoma and drug-resistant GIST targeted therapy experiments, multi-kinase signal pathway verification and modified indole heterocyclic anti-tumor drug synthesis, with broad-spectrum and stable targeted anti-cancer activity.
Q2: What is the structural feature of Sunitinib?
A: Sunitinib has a unique fluorinated indolinone-pyrrole fused heterocyclic structure with diethylaminoethyl amide functional modification. As a special fluoro-substituted indole derivative, it optimizes molecular lipophilicity and target binding affinity, forming efficient multi-target kinase inhibitory activity, which is different from ordinary unmodified indole compounds.
Q3: What are the core advantages of our Sunitinib?
A: Our Sunitinib adopts low-temperature oxygen-free purification and multi-stage recrystallization technology, featuring ultra-high single-component purity, zero fluorinated impurity interference, stable multi-target RTK inhibitory activity and consistent batch efficacy. It effectively avoids experimental errors caused by residual synthesis impurities and molecular degradation, ensuring high-precision tumor pharmacology research results.
Q4: How to store Sunitinib correctly?
A: Sunitinib is sensitive to strong light, high temperature and humid environments, prone to oxidation and molecular isomerization leading to decreased targeted inhibitory activity. It must be stored in vacuum-sealed, low-temperature, cool and dry dark conditions. Standard sealed low-temperature storage ensures 24 months of stable shelf life and pharmacological activity.
Q5: What is the appearance of high-purity Sunitinib?
A: High-purity Sunitinib is uniform yellow to orange crystalline powder at room temperature, odorless, stable crystal state, no caking, no fading and no deterioration precipitation.
Q6: Can I get free Sunitinib samples for testing?
A: Yes, we provide free Sunitinib samples for tumor targeted mechanism research, multi-kinase inhibitory activity verification and fluorinated indole heterocyclic derivative synthesis tests. Bulk orders support customized purity and professional anti-oxidation vacuum packaging to meet high-standard scientific research and pharmaceutical API production needs.
